Celanese Corporation
NYSE:CEChemicals
-$0.24 today
- Market cap
- $5.29B
- Beta
- 0.74
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$9.98
- Dividend yield
- 0.24%
Volume 1.38M
Average 2.09M
CE Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Celanese CorporationNYSE: CE
Revenue · Q2 FY2026 · quarter ended Jun 2026
Revenue growth accelerates
Q2 FY2026 revenue of $2.75B rose 8.7% year over year, ahead of the -2.3% change in trailing-twelve-month revenue. Sequentially, it rose 17.8% from the prior quarter. Over 3 fiscal years it compounded at -0.4% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 12 analysts of $9.99B (+4.7%) for the fiscal year ending Dec 2026, a step up from the -7.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $2.75B+17.8% QoQ
- Last fiscal yearDec 2025
- $9.54B-7.2% YoY
- LTMJun 2026
- $9.71B-2.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +8.7% | +8.4% | -0.3 pp |
| 1 year | -7.2% | +4.7% | +11.9 pp |
| 3-year CAGR | -0.4% | +2.4% | +2.8 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 9.54B USD
- Year-over-year change
- -7.2%
- 4-year CAGR
- +2.8%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.54B | -7.2% |
| FY2024 | 2024-12-31 | 10.28B | -6.0% |
| FY2023 | 2023-12-31 | 10.94B | +13.1% |
| FY2022 | 2022-12-31 | 9.67B | +13.3% |
| FY2021 | 2021-12-31 | 8.54B | — |
Revenue vs competitors
How CE compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -2.3% is the 9th highest of 10, against a peer median of +8.1%.
- Over three fiscal years its annual growth of -0.4% compares with a peer median of +3.2%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| FY2026 | ZAR 266.46B ZAR | +7.0% | -2.7% | |
| LTM Jun 2026 | $9.71B USD | -2.3% | -0.4% | |
| LTM Jun 2026 | $3.63B USD | -4.7% | -4.9% | |
| LTM Aug 2026 | $3.55B USD | +1.5% | -2.5% | |
| LTM Jun 2026 | $1.93B USD | +48.4% | +13.0% | |
| LTM Jun 2026 | $1.84B USD | -1.4% | -8.6% | |
| LTM Jun 2026 | $1.7B USD | +8.1% | +3.9% | |
| LTM Mar 2026 | $1.3B USD | +210.6% | +77.2% | |
| LTM Sep 2026 | $1.14B USD | +9.0% | +5.0% | |
| LTM Sep 2026 | $1.11B USD | +9.4% | +3.2% | |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding CE) | — | +8.1% | +3.2% | |
Competitors are the stored peer set for CE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 8.54B | 9.67B | 10.94B | 10.28B | 9.54B |
| Cost of Revenue | 5.86B | 7.29B | 8.34B | 7.92B | 7.75B |
| Gross Profit | 2.68B | 2.38B | 2.6B | 2.36B | 1.79B |
| Gross Margin | 31.4% | 24.6% | 23.8% | 22.9% | 18.8% |
| Research & Development | 86M | 112M | 146M | 130M | 125M |
| Selling, General & Admin | 633M | 824M | 1.08B | 1.03B | 899M |
| Operating Expenses | 736M | 1B | 916M | 3.05B | 1.02B |
| Depreciation & Amortization | 378M | 478M | 711M | 823M | 786M |
| EBITDA | 2.72B | 2.3B | 2.61B | 503M | 335M |
| EBITDA Margin | 31.8% | 23.8% | 23.9% | 4.9% | 3.5% |
| Operating Income | 1.95B | 1.38B | 1.69B | (697M) | 767M |
| Operating Margin | 22.8% | 14.2% | 15.4% | -6.8% | 8.0% |
| Interest Income | 8M | 69M | 39M | 33M | 24M |
| Interest Expense | 100M | 405M | 720M | 676M | 769M |
| Other Income / Expenses | 302M | 43M | (504M) | (299M) | (1.99B) |
| Income Before Tax | 2.25B | 1.42B | 1.18B | (996M) | (1.22B) |
| Pre-Tax Margin | 26.3% | 14.7% | 10.8% | -9.7% | -12.8% |
| Income Tax Expense | 330M | (489M) | (790M) | 510M | (90M) |
| Net Income | 1.89B | 1.89B | 1.96B | (1.52B) | (1.17B) |
| Net Margin | 22.1% | 19.6% | 17.9% | -14.8% | -12.2% |
| EPS (Basic) | 16.99 | 17.48 | 18.01 | (13.93) | (10.64) |
| EPS (Diluted) | 16.86 | 17.34 | 17.92 | (13.93) | (10.64) |
| Weighted Avg Shares | 111.22M | 108.38M | 108.85M | 109.27M | 109.5M |
| Weighted Avg Shares (Diluted) | 112.08M | 109.24M | 109.38M | 109.27M | 109.5M |
Celanese Corporation
NYSE:CE
Intrinsic Alpha fair value
Locked
Current Price
$48.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.